Cytomos is a technology company.
Cytomos has raised $13.0M across 3 funding rounds.
Cytomos has raised $13.0M in total across 3 funding rounds.
Cytomos has raised $13.0M in total across 3 funding rounds.
Cytomos's investors include Archangel Investors.
Cytomos is an Edinburgh-based biotechnology company developing innovative cell analysis platforms for bioprocessing in biopharma and cell therapy.[1][2][3][4] It builds AuraCyt™ and Celledonia™, integrated predictive analytics systems using Cytomos Dielectric Spectroscopy (CDS) and repurposed microelectronics to enable real-time, label-free single-cell analysis.[2][3][5] These tools serve biopharma companies, cell and gene therapy developers, and TechBio partners by solving bottlenecks in traditional cytometry—such as labeling reagents, complex setups, and delays—offering low-cost, portable, scalable quality control that accelerates drug discovery, streamlines manufacturing, reduces costs, and supports automation.[1][2][3][5] Backed by investors, Cytomos demonstrates growth through partnerships with major biotechs and pharma leaders, positioning it as a key enabler in advanced therapy medicinal products (ATMP).[2][4]
Founded in 2012 in Edinburgh, UK, by CEO Keith Muir, Cytomos emerged as a life science innovator focused on novel cell analysis technologies.[4] The company developed its proprietary platforms in-house, including AuraCyt™ and CDS, driven by a team of experts like Chair Dr. Alan Raymond, Chief Scientific Officer Dr. Lindsay Fraser, and Chief Technology Officer Nick Smith.[2] Early traction came from proof-of-concept studies with large biotechs and pharma partners, highlighting the technology's value in real-time bioprocessing and cell therapy.[2][3] This evolution reflects a purpose-driven mission to repurpose microelectronics for cost-effective biotech scale-up, humanizing the company's push toward becoming the leading process analytic technology (PAT) partner for single-cell analytics.[2]
Cytomos rides the wave of TechBio convergence, where microelectronics meet biotechnology to address surging demand for efficient cell and gene therapies amid ATMP market growth.[2] Timing is ideal as biopharma faces pressures for faster, cheaper manufacturing—real-time PAT like CDS counters scalability hurdles in continuous bioprocessing, influenced by regulatory pushes for automation and cost reduction.[1][3] Market forces like rising cell therapy adoption favor Cytomos, as its platforms integrate with leaders in bioprocessing solutions, influencing the ecosystem by enabling non-specialist access to advanced analytics and accelerating drug development timelines.[2]
Cytomos is poised to dominate real-time single-cell analytics as ATMP and personalized medicine expand, with next steps likely including broader commercialization of Celledonia™, deeper TechBio partnerships, and global scale-up.[2][5] Trends like AI-driven bioprocessing and automation will amplify its edge, potentially evolving its influence from niche innovator to essential infrastructure for biopharma manufacturing. This builds on its investor-backed momentum, promising streamlined development and reduced time-to-market in a high-stakes biotech arena.[2][4]
Cytomos has raised $13.0M across 3 funding rounds. Most recently, it raised $6.0M Venture Round in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $6.0M Venture Round | Archangel Investors | |
| Aug 1, 2023 | $5.0M Series A | Archangel Investors | |
| Jun 1, 2022 | $2.0M Seed | Archangel Investors |